New phase I clinical trial : BikDD nanoparticles in patients with advanced pancreatic cancer


The MD Anderson Cancer Center and the National Cancer Institute plan to start in May 2010 a phase I clinical trial involving a nanoparticle formulation, now registered in the Clinicaltrials.gov database under reference NCT00968604. According to this page, “the goal of this clinical research study is to find the highest tolerable dose of BikDD nanoparticle that can be given to patients with advanced cancer of the pancreas. The safety of this drug will also be studied.

[[[ Additional link suggested by Nanocolors :

Nanoparticles & cancer therapy in biomedical publications since 2000 ]]]

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: